Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis. Issue 12 (22nd December 2020)

• Record Type: Journal Article
• Authors: Vietri, Lucia; d'Alessandro, Miriana; Bergantini, Laura; Carleo, Alfonso; Cameli, Paolo; Mazzei, Maria Antonietta; Sestini, Piersante; Bargagli, Elena
• Is Part Of: Internal medicine journal. Volume 50:Issue 12(2020)
• Page Start: 1571
• Page End: 1574
• Publication Date: 2020-12-22
• Subjects: idiopathic pulmonary fibrosis -- sarcoidosis -- chronic hypersensitivity pneumonitis -- serum amyloid A -- pulmonary Langerhans cell histiocytosis; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.15113
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: Serum amyloid A (SAA) is an apo‐lipoprotein produced by the liver in response to proinflammatory cytokines. Few data are available on SAA levels in patients with idiopathic pulmonary fibrosis (IPF), the most common idiopathic form of interstitial pneumonitis (ILD). This study compared SAA concentration in IPF patients to other ILD groups to explore its potential use as a clinical biomarker.